HR+, HER2-, ADVANCED BREAST CANCER
Clinical trials for HR+, HER2-, ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+, HER2-, ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+, HER2-, ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug called AVZO-023 in people with advanced solid tumors, including a type of breast cancer (HR+/HER2-). The goal is to find a safe dose and see if it can shrink tumors. About 380 adults will take the drug alone or with other treatments.
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:32 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy targets Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests a new two-drug combination for people with advanced breast cancer that has spread or cannot be removed by surgery. The drugs aim to boost the immune system to attack cancer cells while delivering chemotherapy directly to them. About 50 participants will receive t…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for advanced breast cancer patients with specific gene mutation
Disease control AVAILABLEThis program provides access to the drug alpelisib for adults with advanced hormone-positive, HER2-negative breast cancer that has a specific genetic mutation (PIK3CA) and has progressed after standard hormone therapy. It's designed for patients who meet specific health criteria …
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jan 13, 2026 15:13 UTC